JAN vs WELL vs SBRA Stock Comparison

Janus Living, Welltower and Sabra Health Care REIT Prices as of Nov 13, 2026 Peers: Industry group
JAN Janus Living, Inc.
$31.82 +9.8% 1M
Market cap
$7.24B
P/E
–
Revenue (TTM)
$835.56M
Div. yield
–
Healthcare REITs Real Estate
WELL Welltower Inc.
$244.49 +5.3% 1M +28.0% 1Y
Market cap
$177.92B
P/E
106.8x
Revenue (TTM)
$13.79B
Div. yield
–
Healthcare REITs Real Estate
6 wins

Head to Head

11 decided of 12

Welltower leads on 6 of the 12 questions below (Welltower 6, Sabra Health Care REIT 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionJANWELLSBRALeader
Larger companyMarket capitalisation $7.24B $177.92B $5.23B WELL
Cheaper on earningsLower P/E, profitable companies only -3,348x 106.8x 73.1x SBRA
Cheaper on forward earningsLower price / next fiscal year consensus EPS 318.2x 83.2x 53.8x SBRA
Faster revenue growthRevenue growth, trailing twelve months — +39.2% +23.4% WELL
More profitableNet margin, trailing twelve months -0.3% 12.1% 7.8% WELL
Better return on capitalReturn on invested capital -21.2% 0.7% 4.4% SBRA
Less leveragedLower net debt / EBITDA — 4.2x 2.9x SBRA
Higher dividend yieldTrailing dividend yield 0.00% 0.00% -0.06% –
Better 1-year returnPrice return, last 12 months — +28.0% +9.4% WELL
Better 5-year returnAnnualised price return, 5 years — +23.4%/yr +6.7%/yr WELL
Less volatileAnnualised volatility, 1 year 28.9% 23.6% 24.8% WELL
Higher overall scoreMean of the five percentile scores vs peers 25/100 41/100 50/100 SBRA

Percentile Scorecard

JANWELLSBRA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisJANWELLSBRA
Valuation 1 #147 of 149 2 #146 of 149 40 #90 of 149
Growth – 83 #26 of 147 51 #73 of 147
Profitability 26 #107 of 144 27 #105 of 144 56 #64 of 144
Financial Health 72 #43 of 149 89 #18 of 149 85 #24 of 149
Shareholder Returns 2 #136 of 139 5 #132 of 139 17 #115 of 139
Overall 25 41 50
  • JAN ranked among 150 companies in Property REITs
  • WELL ranked among 150 companies in Property REITs
  • SBRA ranked among 150 companies in Property REITs

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodJANWELLSBRASPY
1 month +9.8%+5.3%+6.6% -2.0%
3 months +3.9%+3.8%+0.6% -2.8%
6 months +19.3%+14.4%-1.1% +2.0%
Year to date —+31.7%+7.9% +10.6%
1 year —+28.0%+9.4% +12.2%
3 years —+181.2%+40.5% +68.1%
3 years, per year —+41.2%+12.0% +18.9%
5 years —+185.8%+38.6% +61.4%
5 years, per year —+23.4%+6.7% +10.1%
10 years —+297.4%-0.2% +248.5%
10 years, per year —+14.8%0.0% +13.3%

Risk

MeasureJANWELLSBRASPY
Volatility, 1Y 28.9%23.6%24.8% 13.6%
Downside volatility, 1Y 26.9%25.2%22.5% 13.9%
Beta vs S&P 500, 1Y -0.01-0.01-0.13 1.00
Return / volatility, 1Y —1.180.38 0.90
Max drawdown, 5Y -13.8%-41.6%-38.7% -25.4%
From 52-week high -3.2%-3.1%-8.7% -3.2%
52-week high $32.88$252.22$22.39 $779.14
52-week low $22.88$181.96$17.67 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleJANWELLSBRA
P/E now vs peer median -3,327xmedian 26.1x 106.3xmedian 26.1x 73.1xmedian 26.1x
P/S now vs peer median 8.9xmedian 4.3x 13.0xmedian 4.3x 5.8xmedian 4.3x
EV/EBITDA now vs peer median -10.9xmedian 14.5x 60.7xmedian 14.5x 15.7xmedian 14.5x
P/FCF now vs peer median -3.5xmedian 21.4x -10.0xmedian 21.4x -16.4xmedian 21.4x
P/B now vs peer median 1.8xmedian 1.2x 3.6xmedian 1.2x 1.9xmedian 1.2x
PEG now vs peer median —median 1.75 1.60median 1.75 1.85median 1.75

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsJANWELLSBRA
Revenue $835.56M $13.79B $919.09M
Gross profit – $5.41B –
Operating income -$871.49M $504.64M –
Net income $38.54M $1.75B $71.46M
Free cash flow -$2.15B -$17.96B -$325.53M
EPS (diluted) $-0.01 $2.21 $0.28
Cash & equivalents $338.06M $2.27B $36.24M
Total debt – $15.73B $1.24B
Shares (diluted) 225.97M 754.90M 259.82M
Enterprise value $4.37B $163.95B $4.78B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricJANWELLSBRA
P/E -3,327x 106.3x 73.1x
P/FCF -3.5x -10.0x -16.4x
P/Operating cash flow 30.0x 53.8x 13.4x
P/S 8.9x 13.0x 5.8x
P/B 1.8x 3.6x 1.9x
P/Tangible book 2.0x 3.9x 1.9x
EV/EBITDA -10.9x 60.7x 15.7x
EV/EBIT -8.2x 382.1x 36.1x
EV/Revenue 8.5x 14.0x 7.1x
EV/FCF -3.3x -10.7x -20.1x
EV/Operating cash flow 28.7x 57.9x 16.4x
PEG (3Y EPS CAGR) – 1.60 1.85

Growth

14 metrics
MetricJANWELLSBRA
Revenue growth (1Y) – 39.2% 23.4%
Revenue CAGR (3Y) – 29.1% 12.3%
Gross profit growth (1Y) – 37.1% –
Gross profit CAGR (3Y) – 28.4% –
Operating income growth (1Y) – -66.4% –
Operating income CAGR (3Y) – -16.4% –
Net income growth (1Y) – 80.6% -59.2%
Net income CAGR (3Y) – 86.0% 41.1%
EPS growth (1Y) – 57.6% -61.7%
EPS CAGR (3Y) – 66.2% 39.6%
Operating cash flow growth (1Y) – 19.5% 17.4%
Operating cash flow CAGR (3Y) – 30.9% 11.4%
Free cash flow growth (1Y) – -282.6% -1,239%
Free cash flow CAGR (3Y) – -162.3% -59.7%

Profitability

14 metrics
MetricJANWELLSBRA
Gross margin – 39.2% –
EBITDA margin -78.3% 23.0% 45.3%
Operating margin -104.3% 3.7% –
Pretax margin 4.7% -1.9% 7.1%
Net margin -0.3% 12.1% 7.8%
FCF margin -257.6% -130.2% -35.4%
Operating cash flow margin 29.7% 24.1% 43.6%
Return on equity 1.0% 3.6% 2.5%
Return on assets 0.8% 2.4% 1.3%
Return on invested capital -21.2% 0.7% 4.4%
Return on capital employed – – –
Asset turnover 0.2x 0.2x 0.2x
Cash conversion (OCF / net income) 6.4x 1.9x 5.6x
Stock comp / revenue 0.1% 11.4% 1.5%

Financial Health

11 metrics
MetricJANWELLSBRA
Debt / assets – 21.3% 22.8%
Debt / equity – 0.3x 0.4x
Net debt / EBITDA – 4.2x 2.9x
Debt / FCF – -0.9x -3.8x
Liabilities / assets 21.0% 32.7% 47.7%
Equity / assets 79.0% 67.3% 52.3%
Interest coverage -407.8x 0.7x 1.6x
Current ratio – – –
Quick ratio – – –
Cash ratio – – –
Altman Z-score – – –

Shareholder Returns

7 metrics
MetricJANWELLSBRA
Dividend yield 1.3% 1.3% 7.3%
Net buyback yield -11.2% -5.3% -3.8%
Shareholder yield -9.9% -4.0% 3.5%
Payout ratio (earnings) – – 423.7%
Payout ratio (FCF) – – -93.0%
Dividend growth (1Y) – – -6.0%
Dividend CAGR (3Y) – – -3.0%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusJANWELLSBRA
Forward P/E 318.2xFY2026 83.2xFY2026 53.8xFY2026
EPS, next fiscal year $0.10FY2026 $2.94FY2026 $0.38FY2026
EPS growth, next FY +150.0%FY2026 +111.5%FY2026 -40.6%FY2026
EPS growth, the year after -10.0% +18.0% +94.7%
Revenue, next fiscal year $885.94MFY2026 $13.66BFY2026 $882.92MFY2026
Revenue growth, next FY +27.8%FY2026 +26.0%FY2026 +14.0%FY2026
Revenue growth, the year after +42.3% +18.6% +14.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersJANWELLSBRA
Held by institutions 38.1% 98.3% 100.0%
Institutions holding 162 1,587 464
Change in shares held, QoQ +56.8% +5.6% +0.7%
Institutions buying 137 879 229
Institutions selling 19 475 147
Buyers to sellers 7.21 1.85 1.56

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

JANWELLSBRA
JAN 1.00 0.50 0.54
WELL 0.50 1.00 0.64
SBRA 0.54 0.64 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, JAN, WELL and SBRA?

Welltower (WELL) is the largest by market capitalisation: Janus Living (JAN) $7.24B, Welltower (WELL) $177.92B, Sabra Health Care REIT (SBRA) $5.23B.

Which stock is cheaper, JAN, WELL and SBRA?

Sabra Health Care REIT (SBRA) trades on the lowest price-to-earnings ratio (Janus Living (JAN) -3,348x, Welltower (WELL) 106.8x, Sabra Health Care REIT (SBRA) 73.1x). On next year's consensus earnings, Sabra Health Care REIT (SBRA) is cheapest (Janus Living (JAN) 318.2x, Welltower (WELL) 83.2x, Sabra Health Care REIT (SBRA) 53.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Welltower (WELL) grew revenue fastest over the trailing twelve months: Welltower (WELL) +39.2%, Sabra Health Care REIT (SBRA) +23.4%.

Which company is more profitable?

Welltower (WELL) has the highest net margin (Janus Living (JAN) -0.3%, Welltower (WELL) 12.1%, Sabra Health Care REIT (SBRA) 7.8%). On return on invested capital, Sabra Health Care REIT (SBRA) leads (Janus Living (JAN) -21.2%, Welltower (WELL) 0.7%, Sabra Health Care REIT (SBRA) 4.4%).

Which stock has performed better?

Over the past year Welltower (WELL) returned the most: Welltower (WELL) +28.0%, Sabra Health Care REIT (SBRA) +9.4%. Over five years, Welltower (WELL) compounded fastest (Welltower (WELL) +23.4%/yr, Sabra Health Care REIT (SBRA) +6.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Welltower (WELL) has been the steadiest (Janus Living (JAN) 28.9%, Welltower (WELL) 23.6%, Sabra Health Care REIT (SBRA) 24.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, JAN, WELL and SBRA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Welltower (WELL) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.